BioAge Achieves 86% hsCRP Reduction in Phase 1, Secures $132.3M
BIOA•BioAge reported Phase 1 topline results for BGE-102 showing median 86% hsCRP reduction and 87–93% normalization at 60 mg and 120 mg once daily with no serious adverse events. The company raised $132.3 million in a follow-on offering and plans Phase 2 cardiovascular and Phase 1b/2a diabetic macular edema trials in mid-2026.
1. Phase 1 Topline Results
In April 2026, BioAge reported positive Phase 1 data for BGE-102, its oral NLRP3 inhibitor, at 60 mg and 120 mg once daily. The therapy achieved median 86% reductions in hsCRP and normalized hsCRP (<2 mg/L) in 87–93% of participants, with consistent IL-6 and fibrinogen decreases and no serious adverse events.
2. Upcoming Proof-of-Concept Trials
BioAge plans to initiate a Phase 2 dose-ranging trial of BGE-102 in participants with elevated cardiovascular risk and a Phase 1b/2a trial in diabetic macular edema in mid-2026. Topline data for the cardiovascular study are expected by year end, and DME results are anticipated by mid-2027.
3. Q1 Financial Performance and Funding
For Q1 2026, collaboration revenue rose to $2.8 million from $1.5 million a year earlier, driven by increased work under the Novartis agreement. Research and development expenses grew to $20.4 million, and the company secured $132.3 million in gross proceeds from an upsized follow-on offering.
4. Pipeline Expansion and Collaborations
BioAge continues to advance its APJ agonist programs with an IND filing planned by year-end 2026 and holds strategic collaborations with Novartis on aging targets and Lilly ExploR&D on metabolic aging antibodies.
